IL12B rs6887695 emerged as a potential pharmacogenetic marker associated with favorable ustekinumab outcomes; however, this exploratory and hypothesis-generating finding requires external validation in larger, independent cohorts before clinical application.
Abstract
Background/Objectives: Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), show substantial variability in response to biologic therapies. Ustekinumab, which targets the IL-12/23 pathway, is an established treatment for moderate-to-severe IBD; however, a proportion of patients fail to achieve sustained remission or discontinue treatment over time. This study aimed to evaluate the effectiveness and persistence of ustekinumab and to explore the potential role of pharmacogenetic markers in predicting treatment outcomes. Methods: In this observational cohort study, 98 IBD patients treated with ustekinumab, with or without corticosteroid bridge therapy, in routine clinical practice were enrolled. The primary endpoint was steroid-free remission (SFR) at 12 months, defined as clinical remission without concomitant corticosteroid use, whereas treatment discontinuation was evaluated during follow-up. Genomic DNA was extracted from peripheral blood samples, and four single-nucleotide polymorphisms (SNPs) in selected immune-related genes were analyzed: PTPN2 rs7234029, HLA-C rs10484554, IL23R rs11209026, and IL12B rs6887695. Results: Of the 98 patients included, 73 (74.5%) achieved SFR, whereas 25 (25.5%) did not. Carriers of IL12B rs6887695 variant genotypes showed higher odds of achieving SFR than wild-type patients after adjustment for disease type and baseline disease activity (OR = 4.77; 95% CI, 1.60–14.23; p = 0.005). During follow-up, 16 patients (16.3%) discontinued treatment. Carriers of IL12B rs6887695 variant genotypes also showed a significantly lower hazard of ustekinumab discontinuation than wild-type patients (HR = 0.29; 95% CI, 0.10–0.85; p = 0.024). Conclusions: This study provides real-world evidence supporting the effectiveness and persistence of ustekinumab in IBD patients. IL12B rs6887695 emerged as a potential pharmacogenetic marker associated with favorable ustekinumab outcomes; however, this exploratory and hypothesis-generating finding requires external validation in larger, independent cohorts before clinical application.
Objective Remission in patients with inflammatory bowel disease appears to plateau at 30–50% within the first year of biological monotherapy. Patients with Crohn’s disease (CD) and ulcerative colitis (UC) on monotherapy with biologics or small molecules may face this therapeutic ceiling, not reaching remission in relat...
A. Haase, J. Kelsen, J∅rgen Agnholt et al.· Clinical and Experimental Ga...· 0 citations
RZB is an effective and well-tolerated treatment for moderate-to-severe CD and UC, showing strong clinical and endoscopic outcomes, but further research is needed to assess long-term efficacy and safety.
Muhammad Waqas Afzal, A. Haseeb, Ushna Ali et al.· Medicine· 0 citations
Therapeutic drug monitoring of UST could serve as a valuable approach for optimizing CD therapy and recommendations were made to continue treatment in 43 patients, escalate therapy or shorten the dosing interval in 20 patients, and switch to another biologic agent in 13 patients.
N. J. Jebur, Dheyaa Jabbar Kadhim, Issa Hussein Al Issa· Pharmacia· 0 citations
BACKGROUND AND AIMS
The role of therapeutic drug monitoring (TDM) in optimizing vedolizumab (VDZ) therapy for Crohn's disease (CD) and ulcerative colitis (UC) remains unclear. Prior evidence was limited by small sample size and heterogeneous endpoints. We synthesized the available evidence on the association of VDZ tro...
Mostafa A. Soliman, Alessandra Saraga, A. Gade et al.· Clinical Gastroenterology an...· 1 citation
INTRODUCTION
Ustekinumab (UST), an anti-interleukin-12/23 antibody, is used to treat moderate-to-severe inflammatory bowel disease (IBD). The STOCUSTE study includes IBD patients treated with UST at four teaching hospitals in Stockholm to provide long-term follow-up data. The utility of therapeutic drug monitoring to o...
H. Sabhan, F. Bello, Samer Muhsen et al.· European Journal of Gastroen...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.